The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.16
Bid: 5.82
Ask: 6.50
Change: -0.35 (-5.38%)
Spread: 0.68 (11.684%)
Open: 6.51
High: 0.00
Low: 0.00
Prev. Close: 6.51
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of New Chief Financial Officer

11 Oct 2023 07:00

RNS Number : 6997P
Synairgen plc
11 October 2023

Synairgen plc

('Synairgen' or the 'Company')

Appointment of Joseph Colliver as New Chief Financial Officer

Southampton, UK - 11 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces that Joseph Colliver has been appointed Chief Financial Officer (CFO) and Executive Director with effect from Monday 6 November 2023. In conjunction with this appointment, and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO and Executive Director on Friday 3 November.

Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies.

Richard Marsden, CEO of Synairgen, said: "Joseph's many years of listed company experience, including in the healthcare sector, will stand us in good stead as we progress towards the clinic with our SNG001 strategy. I'd like to thank John for his steadfast commitment, loyalty and support to both me and the Board over many years. We wish him the very best for the future."

Joseph Colliver, newly appointed CFO of Synairgen, commented: "This is a pivotal time for the Company, as it works towards the next phase of clinical trials with SNG001. I look forward to working closely with Richard and the team in the coming months and years."

John Ward, outgoing CFO of Synairgen, commented: "It has been a pleasure to work with the Synairgen team for these many years, driven by the shared vision to develop treatments for severe viral lung infections. However, it's the right time to pass on the baton, and I look forward to following the Company's next steps and wish the team every success with SNG001 in the future."

Information required under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies ("AIM Rules")

Full name:

Joseph Tregonning Colliver

Age:

43

Shares held in the Company:

None

Current directorships:

· Phytome Life Sciences Plc

· Phytome Research Ltd

· Hellenic Dynamics Plc

· Psych Capital Plc

· Colliver Advisory Ltd

Historic directorships in previous 5 years:

· Sativa Wellness Group Inc

· Borganic Consulting Inc

· Olimax NT Sp z o.o.

· Sativa Group Ltd

· Blood Matters Ltd

· Sativa Cultivation and Extraction Limited

· Sativa Wellness Ltd

· Phytovista Laboratories Ltd

· Goodbody Botanicals Ltd

· Tessellate Collective Ltd

· Goodbody and Blunt Ltd

· Sativa Investments Ltd

· Goodbody Wellness Limited

· George Botanicals Ltd

· Sativa Cosmetics Ltd

There is no further information to be disclosed in relation to the appointment pursuant to Rule 17 and Schedule Two, paragraph (g) of the AIM Rules.

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

Synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOABIBDGLUBDGXG
Date   Source Headline
8th Apr 20204:41 pmRNSSecond Price Monitoring Extn
8th Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 20204:56 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSCommencement of dosing in COVID-19 trial
30th Mar 20204:42 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 202011:05 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
30th Mar 20209:05 amRNSSecond Price Monitoring Extn
30th Mar 20209:00 amRNSPrice Monitoring Extension
27th Mar 20203:21 pmRNSHolding(s) in Company
26th Mar 20209:00 amRNSResult of Fundraising
25th Mar 20201:45 pmRNSProposed Fundraising
25th Mar 202011:05 amRNSSecond Price Monitoring Extn
25th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20208:24 amRNSHolding(s) in Company
23rd Mar 202011:05 amRNSSecond Price Monitoring Extn
23rd Mar 202011:00 amRNSPrice Monitoring Extension
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
20th Mar 20202:00 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 20209:05 amRNSSecond Price Monitoring Extn
19th Mar 20209:00 amRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSSynairgen to start trial of SNG001 in COVID-19
10th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Oct 20193:53 pmRNSHoldings in Company
16th Oct 20197:30 amRNSHolding(s) in Company
30th Sep 20197:00 amRNSHalf-year Report
27th Sep 20197:00 amRNSPhase II Biomarker Data for SNG001 to be presented
24th Jul 20197:00 amRNSPhase II Clinical Trial Update
8th Jul 20195:48 pmRNSHoldings in Company
3rd Jun 201911:52 amRNSResult of AGM
18th Apr 20199:20 amRNSDirectorate Change, Annual Report & Notice of AGM
5th Apr 201912:55 pmRNSGrant of Options
14th Mar 20197:00 amRNSPositive DSMC Review of Phase II Study for SNG001
25th Feb 20197:00 amRNSPreliminary results for the year ended 31 Dec 2018
17th Jan 20198:31 amRNSUpdate on LOXL2 programme with Pharmaxis
22nd Oct 201810:05 amRNSHolding(s) in Company
22nd Oct 20187:00 amRNSPart 2 start of Phase II COPD trial
16th Oct 20183:01 pmRNSHolding(s) in Company
15th Oct 20188:49 amRNSHolding(s) in Company
12th Oct 201811:05 amRNSResult of General Meeting
12th Oct 201810:29 amRNSResult of General Meeting
25th Sep 20185:56 pmRNSResult of Fundraise
25th Sep 20181:01 pmRNSProposed Fundraise to raise c.£2.9 million
25th Sep 20181:00 pmRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.